Kura Oncology (KURA) Income towards Parent Company (2010 - 2026)
Kura Oncology (KURA) posted quarterly Income towards Parent Company of -$73.3 million for Q1 2026, down 27.69% year-over-year from -$101.4 million in Q1 2025, and up 9.46% quarter-over-quarter from -$81.0 million in Q4 2025.
Kura Oncology (KURA) Income towards Parent Company (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Income towards Parent Company for 8 consecutive years, with -$73.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 27.69% year-over-year to -$73.3 million; the TTM figure through Mar 2026 stood at -$294.6 million (down 3626.85% YoY), while the FY2025 annual figure was -$278.7 million, down 96996.17% from the prior year.
- Income towards Parent Company advanced to -$73.3 million in Q1 2026 per KURA's latest filing, from -$81.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $154.8 million in Q4 2024 and bottomed at -$81.0 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$39.1 million across 3 years, with a median of -$57.4 million in 2025.
- On a YoY basis, Income towards Parent Company climbed as much as 15.96% in 2025 and fell as far as 152.34% in 2025.
- Kura Oncology's Income towards Parent Company stood at $154.8 million in 2024, then sank by 152.34% to -$81.0 million in 2025, then climbed by 9.46% to -$73.3 million in 2026.
- Business Quant data shows KURA's Income towards Parent Company at -$73.3 million in Q1 2026, -$81.0 million in Q4 2025, and -$74.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.33 Mn |
| Mar 31, 2026 | -73.33 Mn |
| Dec 31, 2025 | -81.00 Mn |
| Sep 30, 2025 | -74.12 Mn |
| Jun 30, 2025 | -66.12 Mn |
| Mar 31, 2025 | -57.43 Mn |
| Dec 31, 2024 | 154.77 Mn |
| Sep 30, 2024 | -54.40 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -49.53 Mn |
| Dec 31, 2014 | -46,762.00 |
| Sep 30, 2014 | -6,428.00 |
| Jun 30, 2014 | -6,887.00 |
| Mar 31, 2014 | -5,766.00 |
| Dec 31, 2013 | -9,750.00 |
| Sep 30, 2013 | -6,139.00 |
| Jun 30, 2013 | -6,749.00 |
| Mar 31, 2013 | -5,973.00 |
| Dec 31, 2012 | -9,662.00 |
| Sep 30, 2012 | -6,013.00 |